| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of 2-Methylquinazolin-4-ol are not well-defined for the compound itself, but its derivatives have been studied as inhibitors of various enzymes, including kinases, phosphodiesterases, and carbonic anhydrases. The quinazolinone scaffold is known to interact with a wide range of biological targets, and the methyl substitution at position 2 may modulate these activities.
|
|---|---|
| ln Vitro |
In a concentration-dependent manner, 2-methylquinazolin-4-ol inhibits ATCase[1].
In vitro, 2-Methylquinazolin-4-ol is often used as a precursor to synthesize more complex compounds that are tested for biological activities. The parent compound may exhibit some intrinsic activity, but it is primarily valued as an intermediate. It has been used in the synthesis of compounds with anticancer, anti-inflammatory, and antimicrobial properties. |
| ln Vivo |
2-Methylquinazolin-4-ol (0.2-1 mg; ig; for two days) suppresses ATCase in vivo in a dose-dependent manner[2].
In vivo, the parent compound is not typically studied as a therapeutic agent, but its derivatives have been evaluated in animal models of disease. For example, some quinazolinone derivatives have shown anticonvulsant activity in mice and anti-inflammatory effects in rat models. The parent compound itself is rarely administered directly. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 2-Methylquinazolin-4-ol are not commonly performed, as it is an intermediate. However, its derivatives are tested against various targets, such as kinases, using standard kinase inhibition assays. The compound itself is typically characterized by NMR, HPLC, and mass spectrometry to confirm its structure and purity.
|
| Cell Assay |
In vitro cellular assays for 2-Methylquinazolin-4-ol are not standard, as it is not a drug candidate. However, its derivatives are tested in cancer cell lines for cytotoxicity, in macrophages for anti-inflammatory activity, and in bacterial cultures for antimicrobial activity. The parent compound may be used as a negative control.
|
| Animal Protocol |
Animal/Disease Models: Mice[2]
Doses: 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg Route of Administration: po (oral gavage), for two days Experimental Results: demonstrated an inhibitory effect upon ATCase. In vivo animal studies are not conducted with 2-Methylquinazolin-4-ol itself. Its derivatives may be tested in animal models for pharmacokinetics, efficacy, and toxicity. The compound is not intended for direct administration. |
| ADME/Pharmacokinetics |
2-Methylquinazolin-4-ol has a molecular formula of C9H8N2O and a molecular weight of 160.17. It appears as a solid powder with a melting point of 245-248°C. It is soluble in organic solvents such as DMSO and ethanol, but sparingly soluble in water. The compound should be stored at room temperature, protected from moisture, and is stable for long periods. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 2-Methylquinazolin-4-ol has not been extensively characterized. As a quinazolinone, it is generally considered to have low acute toxicity. Standard safety precautions should be followed when handling. It is not approved for clinical use.
|
| References | |
| Additional Infomation |
It has been reported that 2-methyl-4(3H)-quinazolinone exists in Streptomyces, Bacillus cereus, and Streptomyces przewalskii, and relevant data are available for reference.
2-Methylquinazolin-4-ol (CAS 1769-24-0) is a heterocyclic compound belonging to the quinazolinone class. It has a molecular formula of C9H8N2O and a molecular weight of 160.17. It is used as a building block in medicinal chemistry for the synthesis of pharmacologically active molecules. Quinazolinones are known for their diverse biological activities, including anticancer, anti-inflammatory, and antimicrobial properties. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C9H8N2O
|
|---|---|
| Molecular Weight |
160.17
|
| Exact Mass |
160.064
|
| CAS # |
1769-24-0
|
| PubChem CID |
135400457
|
| Appearance |
White to off-white solid powder
|
| Density |
1.26 g/cm3
|
| Boiling Point |
305.4ºC at 760 mmHg
|
| Melting Point |
231-233ºC(lit.)
|
| Flash Point |
138.5ºC
|
| LogP |
1.231
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FIEYHAAMDAPVCH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8N2O/c1-6-10-8-5-3-2-4-7(8)9(12)11-6/h2-5H,1H3,(H,10,11,12)
|
| Chemical Name |
2-methyl-3H-quinazolin-4-one
|
| Synonyms |
2-Methylquinazolin-4-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~312.2 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2434 mL | 31.2168 mL | 62.4337 mL | |
| 5 mM | 1.2487 mL | 6.2434 mL | 12.4867 mL | |
| 10 mM | 0.6243 mL | 3.1217 mL | 6.2434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
